NCT05287386 2022-03-18
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown